Navigation Links
ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
Date:5/19/2011

erapeutic options, including C1 esterase inhibitor deficiency, pediatric epilepsy and C. difficile infection (CDI).  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve.  ViroPharma's commercial products address diseases including hereditary angioedema (HAE) and CDI; for prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding the timing and nature of ViroPharma's clinical development programs, including statements that VP 20621 may potentially protect a patient from colonization with toxin-producing strains of C. difficile and VP 20621 may significantly reduce the incidence of recurrent disease for patients with CDI. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The studies described in this press release represent the initial human studies with VP 20621 and the res
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... 12, 2014 Research and Markets ... http://www.researchandmarkets.com/research/ms3j8c/cardiac ) has announced the addition of the ...  report to their offering. Global Guidewires sector is ... North America accounts for nearly 35% ... claims approximately 25% (2018). Asia-Pacific ...
(Date:12/15/2014)... TARRYTOWN, N.Y. and BRIDGEWATER, N.J. ... Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and ... heart disease organizations to launch Cholesterol Counts , ... know about cholesterol, their numbers, and the risks associated ... to visit www. CholesterolCounts .com to take ...
(Date:12/15/2014)... MARCOS, Texas , Dec. 15, 2014  Stephen ... dot manufacturer Quantum Materials Corp (OTCQB:QTMM), will ... Center for Quantum Materials (RCQM) on December 16th, 2014. ... exploration of exotic nanomaterials in attracting top faculty and ... Rice to collaborate on research. "We ...
Breaking Medicine Technology:Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3
... , , , , , , BANGALORE, India ... unique strategy. This is based on the following,elements: , , ... Sino-Indian focus, - Flexible co-development model availability, ... Experience of early stage life science company product development, - ...
... , , CAMBRIDGE, Mass. , ... it has reached an agreement with the U.S. Food and Drug ... trial for Vascugel®, an investigational new drug for the prevention of ... Special Protocol Assessment (SPA) procedure. Pervasis expects to initiate the study ...
Cached Medicine Technology:Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 2Infinitus Clinical Research Consolidates- Sino-Indian CRO Enhances Core Capabilities 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 2Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 3Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R) 4
(Date:12/15/2014)... Health Dialog, a leading provider of ... has received Patient Oriented Accreditation from the National ... Management (DM) Programs for asthma, congestive heart failure, ... and diabetes. This marks the 12th continuous year ... Management (DM) Programs, reaffirming Health Dialog’s focus and ...
(Date:12/15/2014)... Dec. 14, 2014 (HealthDay News) -- Expert pilots process ... explains why they make better decisions during landings, a ... most difficult techniques for pilots to master, and 36 ... fatal crashes occur during final approach and landing. ... and 12 moderately experienced pilots while they were at ...
(Date:12/15/2014)... 2014 Kathy McAfee, America's Marketing Motivator, ... Awards in the category of Best Blog 2014. McAfee ... her weekly career blog Networking Ahead which ... professionals elevate their talent and influence through better networking, ... her book Networking Ahead for Business, has been motivating ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
(Date:12/15/2014)... Bacteroides is becoming the indicator of choice for ... prevalent than coliforms, it cannot reproduce in the presence of ... Key Benefits of the new Bacteroides Sewage Screen:, ... Eliminates false positives from coliforms naturally occurring in the environment ... Maintain the same sampling method with results as quick ...
Breaking Medicine News(10 mins):Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Kathy McAfee, America’s Marketing Motivator, Wins Best Blog from Women World Awards 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... the gold-standard treatment for postoperative and chronic cancer pain ... showing that opiate-based painkillers can stimulate the growth and ... argument and demonstrate how shielding lung cancer cells from ... cell-culture and mouse models. The reports--to be presented ...
... people appear to be fearless, navigating busy sidewalks and ... a cane as a guide. The reason they can ... some circumstances, blindness can heighten other senses, helping individuals ... UCLA Department of Neurology have confirmed that blindness causes ...
... ... , ... Ziosoft®, Inc. http://www.ziosoftinc.com -- a leader in advanced visualization and analysis software for ... marketing, effective November 16., , , , ,Most recently, Royea served as vice president of ...
... , LOUISVILLE, Ky., Nov. 18 ... for its Carewise® Health consumer education and support program ... establishes quality standards for the healthcare industry. , ... education and support accreditation back in 2005, and this ...
... young adults with single-ventricle congenital heart disease who ... sildenafil, a drug used to treat erectile dysfunction ... Hospital of Philadelphia. Single-ventricle defects are ... heart,s ability to pump blood. Examples include tricuspid ...
... , , WASHINGTON, Nov. 18 ... a wholly owned subsidiary of ULLICO Inc., a privately ... Prescription Solutions will provide pharmacy benefit management services to ... union trust funds, union employers and their members with ...
Cached Medicine News:Health News:Common pain relief medication may encourage cancer growth 2Health News:Common pain relief medication may encourage cancer growth 3Health News:UCLA study shows brain's ability to reorganize 2Health News:UCLA study shows brain's ability to reorganize 3Health News:Ziosoft Announces the Appointment of Rob Royea, Vice President, Sales and Marketing 2Health News:SHPS Receives Re-Accreditation from URAC for Consumer Education and Support Program 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: